ArticleJournal of inflammation research2025
The Prognostic Role of Naples Prognostic Score in Patients with Coronary Artery Disease.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association of naples prognostic score and systemic immune-inflammation index with left ventricular recovery in peripartum cardiomyopathy.BMC cardiovascular disorders · 2026Article
- The Naples Prognostic Score May Predict No Reflow in Patients Undergoing Percutaneous Coronary Intervention for Saphenous Vein Graft Stenosis.Diagnostics (Basel, Switzerland) · 2026Article
- The Association Between Naples Prognostic Score and Coronary Collateral Circulation in Patients with Chronic Coronary Total Occlusion.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: The Naples Prognostic Score (NPS) is a tool for assessing inflammation and nutrition, widely used in outcome evaluation. However, its association with adverse outcomes in patients with coronary artery disease (CAD) has not been explored. This study aims to investigate the prognostic value of NPS in CAD patients. Methods: This retrospective cohort study included 2453 patients with CAD who visited the Fujian Heart Medical Center between 2017 and 2022. Patients were divided into three groups based on NPS. The NPS was calculated based on serum albumin, total cholesterol, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio. Univariate and multivariate regression analyses, along with Cox models, were used to assess the impact of NPS on adverse outcomes. Receiver operating characteristic (ROC) curves evaluated NPS's accuracy in predicting all-cause in-hospital mortality. Results: Patients with lower NPS scores are less likely to have comorbidities such as hyperlipidemia and chronic kidney disease. Additionally, they tend to use fewer medications for treatment. Multivariate analysis revealed that elevated NPS levels were independently associated with poorer clinical outcomes. Compared to group 1, the risk of all-cause mortality was significantly higher in groups 2 and 3 [group 2, adjusted odds ratio (aOR)=0.33; group 3, aOR=1.82; Conclusion: This study suggests that the NPS, a novel metric integrating inflammation and nutritional status, is closely associated with the prognosis of CAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.